CTI BioPharma (CTIC) Getting Somewhat Favorable Press Coverage, Accern Reports

News articles about CTI BioPharma (NASDAQ:CTIC) have trended somewhat positive this week, according to Accern. The research firm identifies positive and negative press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. CTI BioPharma earned a news sentiment score of 0.19 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 45.7589802701163 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

CTI BioPharma (NASDAQ CTIC) opened at $2.51 on Friday. CTI BioPharma has a 1-year low of $2.45 and a 1-year high of $6.48. The company has a current ratio of 2.19, a quick ratio of 2.17 and a debt-to-equity ratio of 0.26.

CTI BioPharma (NASDAQ:CTIC) last released its quarterly earnings results on Monday, November 6th. The biopharmaceutical company reported ($0.28) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.32) by $0.04. The company had revenue of $1.71 million during the quarter, compared to analysts’ expectations of $0.30 million. CTI BioPharma had a negative net margin of 96.91% and a negative return on equity of 209.67%. equities research analysts expect that CTI BioPharma will post -1.2 EPS for the current fiscal year.

Several research analysts have recently weighed in on CTIC shares. Jefferies Group started coverage on shares of CTI BioPharma in a report on Tuesday, September 12th. They issued a “buy” rating and a $7.50 price target for the company. ValuEngine cut shares of CTI BioPharma from a “sell” rating to a “strong sell” rating in a report on Wednesday, October 11th.

In other news, Director Richard L. Love sold 14,600 shares of the business’s stock in a transaction on Friday, September 29th. The shares were sold at an average price of $3.21, for a total value of $46,866.00. Following the sale, the director now owns 84,318 shares of the company’s stock, valued at $270,660.78. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 8.08% of the company’s stock.

TRADEMARK VIOLATION WARNING: “CTI BioPharma (CTIC) Getting Somewhat Favorable Press Coverage, Accern Reports” was originally reported by TrueBlueTribune and is owned by of TrueBlueTribune. If you are reading this piece on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright law. The correct version of this piece can be viewed at https://www.truebluetribune.com/2017/12/15/cti-biopharma-ctic-getting-somewhat-favorable-press-coverage-accern-reports.html.

About CTI BioPharma

CTI BioPharma Corp. (CTI) is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL).

Insider Buying and Selling by Quarter for CTI BioPharma (NASDAQ:CTIC)

Receive News & Ratings for CTI BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CTI BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply